Anti-saccade Error Rates As a Measure of Attentional Bias in Cocaine Dependent Subjects
Overview
Psychology
Social Sciences
Authors
Affiliations
Cocaine-dependent (CD) subjects show attentional bias toward cocaine-related cues, and this form of cue-reactivity may be predictive of craving and relapse. Attentional bias has previously been assessed by models that present drug-relevant stimuli and measure physiological and behavioral reactivity (often reaction time). Studies of several CNS diseases outside of substance use disorders consistently report anti-saccade deficits, suggesting a compromise in the interplay between higher-order cortical processes in voluntary eye control (i.e., anti-saccades) and reflexive saccades driven more by involuntary midbrain perceptual input (i.e., pro-saccades). Here, we describe a novel attentional-bias task developed by using measurements of saccadic eye movements in the presence of cocaine-specific stimuli, combining previously unique research domains to capitalize on their respective experimental and conceptual strengths. CD subjects (N = 46) and healthy controls (N = 41) were tested on blocks of pro-saccade and anti-saccade trials featuring cocaine and neutral stimuli (pictures). Analyses of eye-movement data indicated (1) greater overall anti-saccade errors in the CD group; (2) greater attentional bias in CD subjects as measured by anti-saccade errors to cocaine-specific (relative to neutral) stimuli; and (3) no differences in pro-saccade error rates. Attentional bias was correlated with scores on the obsessive-compulsive cocaine scale. The results demonstrate increased saliency and differential attentional to cocaine cues by the CD group. The assay provides a sensitive index of saccadic (visual inhibitory) control, a specific index of attentional bias to drug-relevant cues, and preliminary insight into the visual circuitry that may contribute to drug-specific cue reactivity.
Biased processing of game-related information in problematic mobile gaming users.
Bai Y, Elhai J, Montag C, Yang H J Behav Addict. 2023; 12(2):480-489.
PMID: 37352094 PMC: 10316168. DOI: 10.1556/2006.2023.00031.
de Dios C, Suchting R, Webber H, Yoon J, Yammine L, Vincent J J Psychopharmacol. 2021; 35(5):611-614.
PMID: 33586502 PMC: 8480541. DOI: 10.1177/0269881121991566.
Maurage P, Bollen Z, Masson N, DHondt F Neuropsychol Rev. 2020; 31(1):167-201.
PMID: 33099714 DOI: 10.1007/s11065-020-09458-0.
Ranjbar S, Mazidi M, Sharpe L, Dehghani M, Khatibi A Sci Rep. 2020; 10(1):12885.
PMID: 32732895 PMC: 7393078. DOI: 10.1038/s41598-020-69910-2.
Tannous J, Mwangi B, Hasan K, Narayana P, Steinberg J, Walss-Bass C PLoS One. 2019; 14(1):e0199729.
PMID: 30625144 PMC: 6326479. DOI: 10.1371/journal.pone.0199729.